NCT06152523 2026-04-06
MONAMI
Assistance Publique - Hôpitaux de Paris
Phase 2 Withdrawn
Clinical Trials
29 trialsNCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04271436 2025-01-07
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Washington University School of Medicine
Phase 2 Withdrawn
NCT05589857 2024-10-23
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03003195 2024-09-03
The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients
University of Arkansas
Phase 2 Withdrawn
NCT04023240 2024-08-12
68-Ga-FAPI PET Imaging in Malignancy
Stanford University
Phase 2 Withdrawn
NCT03044795 2024-05-03
REPAIR
University Medical Center Groningen
Phase 2 Withdrawn
NCT04985825 2022-09-13
I-PACE
Centessa Pharmaceuticals plc
Phase 2 Withdrawn
NCT04809012 2022-03-25
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT00624312 2021-08-06
Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations
University of Louisville
Phase 2 Withdrawn
NCT03832673 2021-02-26
PECULIAR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Withdrawn
NCT04398927 2021-02-04
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03348826 2020-09-16
Study of Sodium Bicarbonate in Restoring Blocked Catheters
University Health Network, Toronto
Phase 2 Withdrawn
NCT03029416 2018-10-15
Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
University of Kentucky
Phase 2 Withdrawn
NCT03123744 2018-06-21
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
University of California, San Diego
Phase 2 Withdrawn
NCT02856867 2017-05-09
MEGAN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT02014831 2016-02-25
PENILANE
Centre Leon Berard
Phase 2 Withdrawn
NCT02035124 2016-02-11
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
SCRI Development Innovations, LLC
Phase 2 Withdrawn
NCT02323516 2015-12-08
ASPIDIA
Centre Francois Baclesse
Phase 2 Withdrawn
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT01828502 2014-10-29
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer
University of South Florida
Phase 2 Withdrawn
NCT01636128 2014-07-30
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Cancer Prevention Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT01663415 2012-09-17
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc
Phase 2 Withdrawn
NCT00605709 2012-07-25
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
BPGbio
Phase 2 Withdrawn
NCT00348842 2011-04-08
Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities
Hadassah Medical Organization
Phase 2 Withdrawn